Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

Background High lipoprotein (a) concentrations present in 10%–20% of the population have
long been linked to increased risk of ischemic cardiovascular disease. It is unclear whether …

Abstract Lipoprotein (a)[Lp (a)] is a well-recognized, independent risk factor for
atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in …

Evidence that elevated lipoprotein (a)(Lp [a]) levels contribute to cardiovascular disease
(CVD) and calcific aortic valve stenosis (CAVS) is substantial. Development of isoform …

Background The role of aspirin in reducing lipoprotein (a)-mediated atherothrombotic events
in primary prevention is not established. Objectives This study sought to assess whether low …

Abstract Lipoprotein (a), Lp (a), is a modified atherogenic low-density lipoprotein particle that
contains apolipoprotein (a). Its levels are highly heritable and variable in the population …

Objective: This paper discusses the evolution of pervasive healthcare from its inception for
activity recognition using wearable sensors to the future of sensing implant deployment and …

Plasma lipoprotein (a)[L p (a)] is a quantitative genetic trait with a very broad and skewed
distribution, which is largely controlled by genetic variants at the LPA locus on chromosome …

Background An increased level of Lp (a) lipoprotein has been identified as a risk factor for
coronary artery disease that is highly heritable. The genetic determinants of the Lp (a) …

Abstract In 2022, the European Atherosclerosis Society (EAS) published a new consensus
statement on lipoprotein (a)[Lp (a)], summarizing current knowledge about its causal …